Substance / Medication

Ranitidine bismuth citrate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Duodenal ulcer disease

Zollinger-Ellison syndrome

Gastroesophageal reflux disease

Gastric ulcer

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.

Gisbert J P, González L, Calvet X et al. · Aliment Pharmacol Ther · 2000

PMID: 10971230Meta-Analysis

Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.

Yoon Jin Young, Kwak Min Seob, Jeon Jung Won et al. · Tohoku J Exp Med · 2021

PMID: 34526429RCT

The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.

Akyildiz Murat, Akay Sinan, Musoglu Ahmet et al. · Eur J Intern Med · 2009

PMID: 19237093RCT

Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.

Kiliç Zeki Mesut Yalin, Köksal Aydin Seref, Cakal Başak et al. · Dig Dis Sci · 2008

PMID: 18465244RCT

A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.

Avşar Erol, Tiftikçi Arzu, Poturoğlu Sule et al. · Turk J Gastroenterol · 2013

PMID: 24254262Observational

Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.

Gisbert Javier P, Gisbert Jose Luis, Marcos Santiago et al. · Helicobacter · 2007

PMID: 17241304Observational

Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study.

Tam Y H, Yeung C K, Lee K H · Aliment Pharmacol Ther · 2006

PMID: 16803605Observational

Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.

Gisbert Javier P, Gonzalez Leticia, Calvet Xavier · Helicobacter · 2005

PMID: 15904473Observational

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole.

Janssen M J, Van Oijen A H, Verbeek A L et al. · Aliment Pharmacol Ther · 2001

PMID: 11328254Observational

Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.

Yuan Shuofeng, Wang Runming, Chan Jasper Fuk-Woo et al. · Nat Microbiol · 2020

PMID: 33028965Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ranitidine bismuth citrate (substance)
SNOMED CT: 386886000
UMLS CUI: C0139919

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.